CytomX Therapeutics, Inc. (CTMX): Earnings News

CTMX – Seeing EPS loss estimates beat range from $0.42-$0.49. Beats on revenues.

Key Facts Surrounding This News Item

  • CTMX had a POWR Rating of A (Strong Buy) coming into today.
  • CTMX was 6.98% above its 10-Day Moving Average coming into today.
  • CTMX was 11.95% above its 20-Day Moving Average coming into today.
  • CTMX was 22.51% above its 50-Day Moving Average coming into today.
  • CTMX was 37.90% above its 100-Day Moving Average coming into today.
  • CTMX was 65.65% above its 200-Day Moving Average coming into today.
  • CTMX had returned +53.29% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California. View our full CTMX ticker page with ratings, news, and more.

Try Premium Today!

Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

CTMX at a Glance

CTMX Current POWR Rating™
Overall POWR Rating™
CTMX Current Price $18.84 0.69%
More CTMX Ratings, Data, and News

CTMX Price Reaction

The day of this event (Mar. 7, 2018)
CTMX Closing Price$33.87 4.67%
CTMX Volume398,200
24.86% from avg
Leading up to this event
CTMX 1-mo return15.57%
After this event
CTMX 1-day return0.37%
CTMX 3-day return5.44%
CTMX 5-day return4.91%

CTMX Price Chart

More CytomX Therapeutics, Inc. (CTMX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CTMX News
Page generated in 1.1225 seconds.